Today: 3 May 2026
Browse Category

NYSE:LLY 15 January 2026 - 23 January 2026

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly stock slips as Novo’s Wegovy pill racks up 18,000+ scripts; earnings next

Eli Lilly shares fell 1.1% to $1,075.78 after Novo Nordisk’s new Wegovy pill logged over 18,000 U.S. prescriptions in its first full week. Investors are watching ahead of Lilly’s Feb. 4 earnings and an expected FDA decision on its own oral obesity drug by April. Several Lilly directors recently received stock units through a deferral plan.
23 January 2026
····
Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly shares rose 0.8% after hours Thursday to $1,087.38. A Reuters report cited nference data showing 36% of patients who stopped Lilly’s weight-loss drug tirzepatide kept weight off after six months, while 28% regained weight. Lilly director Juan R. Luciano acquired 15.286 shares via a deferral plan, per SEC filing. The company reports Q4 earnings February 4.
23 January 2026
···
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly shares rose 3.6% to $1,078.52 Wednesday after the FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. The company will report fourth-quarter earnings on February 4. Director Juan R. Luciano disclosed acquiring about 15 shares through deferred board compensation.
21 January 2026
···
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·
Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly stock price edges higher after FDA breakthrough nod for ovarian cancer drug

Eli Lilly shares rose about 0.2% Tuesday after the FDA granted Breakthrough Therapy designation to its experimental ovarian cancer drug, sofetabart mipitecan. The stock traded near $1,040 as the broader market fell 1%. The designation covers patients with platinum-resistant disease who have tried other therapies. Bernstein maintained its Outperform rating and $1,300 price target.
20 January 2026
··
Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly shares closed Friday at $1,038.40, up 0.5% after trading between $1,019 and $1,049.83. Investors are watching for FDA decisions on Lilly’s obesity pill and tracking early prescription data as Novo Nordisk’s Wegovy pill posts strong initial sales. U.S. markets will be closed Monday, reopening Tuesday. Lilly’s next earnings call is scheduled for February 4.
18 January 2026
··
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly shares rose 0.5% to $1,038.40 Friday as the FDA set April 10 as the new target date for a decision on its experimental weight-loss pill. The agency delayed review timelines for several drugs, including Lilly’s, under its fast-track program. Novo Nordisk’s new Wegovy pill saw about 3,071 U.S. prescriptions in its first four days, according to IQVIA data.
17 January 2026
··
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
17 January 2026
···
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly shares rose 0.5% in after-hours trading after the FDA delayed its decision on the company’s obesity drug orforglipron to April 10. Lilly and Novo Nordisk face a lawsuit from Texas-based Strive Specialties, which alleges both companies restricted access to cheaper compounded versions of GLP-1 drugs. Lilly also disclosed a 10% stake in Aktis Oncology.
17 January 2026
··
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly shares fell 3.8% premarket to $1,033 after FDA documents set an April 10 decision date for its weight-loss pill under a fast-track program. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging efforts to block cheaper compounded GLP-1 drugs. Novo Nordisk shares dropped 3%. Investors await further FDA guidance and Lilly’s Feb. 4 earnings call.
16 January 2026
··
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 3.8% to $1,032.97 in after-hours trading after the FDA delayed its decision on the company’s obesity pill to April 10. A Texas compounding pharmacy filed a new lawsuit against Lilly and Novo Nordisk, alleging efforts to block access to cheaper alternatives. Investors are watching Lilly’s Feb. 4 earnings call and the FDA’s April decision as key dates.
15 January 2026
··
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Eli Lilly shares fell 4.7% to $1,022.50 after Reuters reported the FDA delayed its decision on the company’s experimental weight-loss pill to April 10. Strive Specialties sued Lilly and Novo Nordisk in Texas, alleging anticompetitive practices tied to GLP-1 drugs. Novo Nordisk shares dropped 3.6%. Investors await Lilly’s Feb. 4 earnings for updates on the pill’s timeline and legal risks.
15 January 2026
·
1 2 3 4 5 6 … 12

Stock Market Today

  • Top UK Stocks to Buy Now: AstraZeneca and Unilever Lead the Picks
    May 3, 2026, 3:19 AM EDT. With the average British saver holding £9,633.30 in low-yield bank accounts, investing in stocks could offer better returns over time. Experts highlight AstraZeneca for its strong oncology pipeline and ambitious $80 billion revenue target by 2030 despite risks like US drug pricing reforms and investigations in China. Unilever is also favored for its robust growth and defensive qualities, currently undergoing a major restructuring by spinning off its food division and merging with McCormick. However, concerns remain over the merger's execution and potential shareholder pushback. Both stocks present opportunities and risks amid a challenging economic backdrop.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 03.05.2026

3 May 2026
Rivian shares fell 8.4% to $15.02 after first-quarter results beat expectations, as investors focused on cash burn and profitability concerns. Trading volume jumped 78% above average. The company plans to ramp up R2 SUV production in Georgia to 300,000 units annually. Tesla and Lucid Group shares both rose more than 2%.
Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
Go toTop